It is with deep sorrow and immense respect that the International Society for Children’s Bone Health (ISCBH) honors the extraordinary life and legacy of Dr. Francis H. Glorieux.
Dr. Glorieux has transformed the care of thousands of children and families worldwide living with pediatric bone disorders. He held a truly special place in the hearts of his patients, who felt genuinely heard, respected, and empowered by him. He was driven by a strong conviction and sincere desire to improve their lives. He continued to support patients in need until the end of his life.
In 1972, Dr. Glorieux was instrumental in establishing the combined use of active vitamin D and oral inorganic phosphate supplementation as the standard therapeutic approach for X-linked hypophosphatemic rickets. In 1998, he and his colleagues demonstrated that intravenous bisphosphonate therapy produced substantial improvements in bone density, fracture rate, and pain in children with severe osteogenesis imperfecta, fundamentally changing the standard of care for this disorder. The protocols developed at Shriners Children’s Canada have been widely adopted internationally, and are now recognized as the standard of care, enhancing quality of life for children with bone fragility.
Dr. Glorieux has contributed to discoveries of several novel genetic forms of osteogenesis imperfecta fundamentally expanding the clinical and molecular understanding of the disease, shifting the paradigm from a disorder solely of type I collagen defects to a genetically and mechanistically heterogeneous group of diseases. Dr. Glorieux also pioneered work in pediatric bone histomorphometry and provided the first comprehensive set of normative data in healthy children and adolescents, supporting the use of bone histomorphometry as the gold standard for evaluating bone metabolism and pathology in the pediatric population.
Dr. Glorieux has mentored and inspired countless clinicians and researchers who now dedicate their lives to caring for children with bone diseases around the world. His enduring influence lives on in the global community he helped build—one rooted in excellence, collaboration, and an unwavering commitment to improving the lives of children with bone disorders. In 2024, the Canadian Osteogenesis Imperfecta Society inaugurated the Francis Glorieux Research Fellowship to support new investigators conducting research in the field of osteogenesis imperfecta.
In 1999, he was the first recipient of the Charles Slemenda Award, established by ISCBH in recognition of outstanding contributions to children’s bone research. This was just one of many awards and accolades Dr Glorieux received throughout his career.
Dr. Glorieux’s legacy is one of profound transformation—scientifically, through groundbreaking advances, and humanistically, through kindness and sincere respect he showed those he cared for and the community he built. Dr. Glorieux’s presence lives on in the gratitude, strength, and love of the families he so deeply touched, and in the dedication and compassion of the clinicians he mentored—his legacy enduring through all they continue to do in his memory.
